The Pharmacologic Assessment of A Novel Lymphocyte Function-Associated Antigen-1 Antagonist (SAR 1118) for the Treatment of Keratoconjunctivitis Sicca in Dogs
Investigative Ophthalmology & Visual Science2011Vol. 52(6), pp. 3174–3174
Citations Over TimeTop 10% of 2011 papers
Christopher J. Murphy, Ellison Bentley, P. Elliott Miller, Kim McIntyre, Gary Leatherberry, Richard R. Dubielzig, Elizabeth A. Giuliano, Cecil P. Moore, Thomas E. Phillips, P.Blaise Smith, Elizabeth Prescott, Jacqueline M. Miller, Peter Thomas, Randall H. Scagliotti, Doug W. Esson, Tom Gadek, Charles O’Neill
Abstract
SAR 1118 appears to be an effective anti-inflammatory treatment for KCS. Additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.
Related Papers
- → Changes in the Surface Expression of Intercellular Adhesion Molecule 3, the Induction of Apoptosis, and the Inhibition of Cell-Cycle Progression of Human Multidrug-Resistant Jurkat/A4 Cells Exposed to a Random Positioning Machine(2020)18 cited
- → [Oridonin inhibits proliferation of Jurkat cells via the down-regulation of Brg1].(2017)1 cited
- [MEKK2 regulates the production of interleukin 2].(2005)
- Effect of Programmed Death Ligand-1 signal on activity and apoptosis of Jurkat cell.(2010)
- Establishment of A Muti-Drug Resistance Cell Line Derived from Human T Lymphocyte Leukemia Cells and Its Biological Features(2011)